LONGEVERON INC-A (LGVN) Stock Price, Quote, News and Overview
NASDAQ:LGVN - Nasdaq - US54303L2034 - Common Stock - Currency: USD
LGVN Quote, Performance and Key Statistics
1.24
-0.07 (-5.34%)
The current stock price of LGVN is 1.24 USD. In the past month the price decreased by -20.51%. In the past year, price increased by 12.73%.
LGVN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.12 | 328.74B | ||
| AMGN | AMGEN INC | 13.88 | 154.96B | ||
| GILD | GILEAD SCIENCES INC | 14.22 | 136.93B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.52B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.06 | 52.94B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.71B | ||
| ARGX | ARGENX SE - ADR | 99.7 | 35.00B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.29 | 26.55B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.03B | ||
| NTRA | NATERA INC | N/A | 21.54B | ||
| BIIB | BIOGEN INC | 8.2 | 19.02B | ||
| UTHR | UNITED THERAPEUTICS CORP | 12.72 | 14.38B |
Related stock screener links
About LGVN
Company Profile
Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. The company is headquartered in Miami, Florida and currently employs 25 full-time employees. The company went IPO on 2021-02-12. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The firm is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Company Info
LONGEVERON INC-A
1951 NW 7th Ave, Ste 520
Miami FLORIDA 33136 US
CEO: Geoff Green
Employees: 24
Phone: 13053027158
LONGEVERON INC-A / LGVN FAQ
What is the stock price of LONGEVERON INC-A today?
The current stock price of LGVN is 1.24 USD. The price decreased by -5.34% in the last trading session.
What is the ticker symbol for LONGEVERON INC-A stock?
The exchange symbol of LONGEVERON INC-A is LGVN and it is listed on the Nasdaq exchange.
On which exchange is LGVN stock listed?
LGVN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LONGEVERON INC-A stock?
9 analysts have analysed LGVN and the average price target is 9.05 USD. This implies a price increase of 630.04% is expected in the next year compared to the current price of 1.24. Check the LONGEVERON INC-A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LONGEVERON INC-A worth?
LONGEVERON INC-A (LGVN) has a market capitalization of 18.61M USD. This makes LGVN a Nano Cap stock.
How many employees does LONGEVERON INC-A have?
LONGEVERON INC-A (LGVN) currently has 24 employees.
What are the support and resistance levels for LONGEVERON INC-A (LGVN) stock?
LONGEVERON INC-A (LGVN) has a resistance level at 1.61. Check the full technical report for a detailed analysis of LGVN support and resistance levels.
Is LONGEVERON INC-A (LGVN) expected to grow?
The Revenue of LONGEVERON INC-A (LGVN) is expected to grow by 2.09% in the next year. Check the estimates tab for more information on the LGVN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy LONGEVERON INC-A (LGVN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LGVN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LGVN, evaluating the profitability, health, valuation and growth aspects
- LONGEVERON INC-A (LGVN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LONGEVERON INC-A (LGVN) Sales and EPS estimates to see what analysts future expectations are.
- LONGEVERON INC-A (LGVN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LONGEVERON INC-A (LGVN) Insider and Institutional Ownership to learn about the owners and their transactions.
- LONGEVERON INC-A (LGVN) Stock Chart to make your own analysis
- LONGEVERON INC-A (LGVN) Latest news and press-releases to stay up to date.
Does LONGEVERON INC-A (LGVN) stock pay dividends?
LGVN does not pay a dividend.
What is the Price/Earnings (PE) ratio of LONGEVERON INC-A (LGVN)?
LONGEVERON INC-A (LGVN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.94).
What is the Short Interest ratio of LONGEVERON INC-A (LGVN) stock?
The outstanding short interest for LONGEVERON INC-A (LGVN) is 4.46% of its float. Check the ownership tab for more information on the LGVN short interest.
LGVN Technical Analysis
LGVN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to LGVN. LGVN has a great financial health rating, but its profitability evaluates not so good.
LGVN Financial Highlights
Over the last trailing twelve months LGVN reported a non-GAAP Earnings per Share(EPS) of -2.94. The EPS increased by 69.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -122.67% | ||
| ROE | -149.05% | ||
| Debt/Equity | 0 |
LGVN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to LGVN. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 68.38% and a revenue growth 2.09% for LGVN